Background In July 2018 the active transcutaneous bone conduction hearing implant
received FDA approval in the US (for patients 12 years and older with conductive and/or …

Abstract Aim This European multicentric study aimed to prove safety and performance of the
Bonebridge BCI 602 in children and adults suffering from either conductive hearing loss …

Purpose (1) To assess the effectiveness and safety of a bone-conduction implant, the
Bonebridge BCI 602, in adults with conductive or mixed hearing loss.(2) To investigate …

Purpose Aim of the study was to evaluate the surgical, clinical and audiological outcome of
32 implantations of the Bonebridge, a semi-implantable transcutaneous active bone …

Purpose Bone conduction hearing devices are widely used and indicated in cases of
conductive, mixed or single-sided deafness where the conventional hearing aids are not …

Background: the Bonebridge hearing implant is an active transcutaneous bone conduction
implant suitable for various types of hearing loss. It was first launched in 2012 as the BCI …

Purpose The study aimed to evaluate audiological benefits, quality of hearing and safety of
two Bonebridge generation: BCI601 and BCI602 (MED-EL, Innsbruck, Austria) in children …

Introduction For children with conductive or mixed hearing loss, in whom use of conventional
hearing aids is impossible or limited, use of bone conduction devices is recommended. The …

Background: Considering that hearing loss has a significant impact on social functioning,
everyday activity and a person's emotional state, one of the most important goals of hearing …

Objective: Investigation of long-term safety and performance of an active, transcutaneous
bone conduction implant in adults and children up to 36 months post-implantation. Study …